Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Erlotinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Erlotinib. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-001593-18 Sponsor Protocol Number: 958 Start Date*: 2015-06-02
    Sponsor Name:Medizinische Universiät Wien
    Full Title: A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans
    Medical condition: Investigation in volunteers only
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000390-30 Sponsor Protocol Number: ML20128 Start Date*: 2006-05-18
    Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
    Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
    Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001597-15 Sponsor Protocol Number: MERLOT Start Date*: 2016-12-19
    Sponsor Name:Erasmus MC cancer institute
    Full Title: Influence of a fatty beverage (Milk) on the absorption of erlotinib: a randomized, cross-over pharmacokinetic study (MERLOT-study)
    Medical condition: Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000967-25 Sponsor Protocol Number: ThoRaT Start Date*: 2012-08-24
    Sponsor Name:
    Full Title: Concomitant Radiotherapy and Erlotinib in advanced lung cancer ThoRaT-studien Thoracal Radiotherapy and Tarceva® An open randomized multicenter phase II study
    Medical condition: Non-small cell lung cancer, - palliative treatment
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002895-32 Sponsor Protocol Number: ML21308 Start Date*: 2007-08-29
    Sponsor Name:Roche AB
    Full Title: A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash
    Medical condition: Erlotinib associated rash
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000349-59 Sponsor Protocol Number: 0244190615-02 Start Date*: 2014-05-12
    Sponsor Name:department of experimental and clinical medicine "F. Magrassi"
    Full Title: METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Medical condition: Patients with metastatic non small cell lung cancer in second line therapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004350-29 Sponsor Protocol Number: ERLO-PK Start Date*: 2012-12-05
    Sponsor Name:herlev hospital
    Full Title: Variations in plasma concentration in patients with non-small cell lung cancer on fixed-dose erlotinib
    Medical condition: Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004625-14 Sponsor Protocol Number: 07-001 Start Date*: 2008-09-11
    Sponsor Name:VU University Medical Centre
    Full Title: A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy
    Medical condition: Advanced non small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001241-84 Sponsor Protocol Number: CINC280B2201 Start Date*: 2015-08-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Completed) NL (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003813-15 Sponsor Protocol Number: CONKO-005 Start Date*: 2007-11-26
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie
    Medical condition: pancreatic cancer adjuvant therapy after R0-resection Gemcitabine plus Erlotinib vs. Gemcitabine mono, given over 24 weeks randomised trial
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005523-15 Sponsor Protocol Number: ulcn0107 Start Date*: 2008-07-17
    Sponsor Name:Radboud University Medical Centre
    Full Title: A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small ce...
    Medical condition: advanced non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004961-42 Sponsor Protocol Number: PET_imaging_of_kinase_inhibitors Start Date*: 2013-05-23
    Sponsor Name:Medical Oncology, VUmc
    Full Title: Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies
    Medical condition: Advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005477-31 Sponsor Protocol Number: I4C-MC-JTBC Start Date*: 2013-08-27
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000370-19 Sponsor Protocol Number: CO-1686-022 Start Date*: 2015-01-14
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003860-11 Sponsor Protocol Number: NL60690.029.17 Start Date*: 2018-05-04
    Sponsor Name:VU University Medical Center
    Full Title: 11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET
    Medical condition: This study will be performed in children suffering from Diffuse Intrinsic Pontine Glioma (DIPG), who are being treated with erlotinib, and have reached steady state plasma concentrations.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003751-37 Sponsor Protocol Number: BO21128 Start Date*: 2008-05-29
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) LT (Completed) GR (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2013-000868-29 Sponsor Protocol Number: GO28758 Start Date*: 2013-08-27
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST LINE TREATMENT FOR PATIENTS WIT...
    Medical condition: Non-Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003603-19 Sponsor Protocol Number: Erlotinib_cola Start Date*: 2014-03-11
    Sponsor Name:Erasmus University Medical Center
    Full Title: Influence of an acidic beverage on the absorption of erlotinib
    Medical condition: Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004124-39 Sponsor Protocol Number: ML19182 Start Date*: 2006-01-13
    Sponsor Name:Dr. Enrique Martínez López
    Full Title: Ensayo clínico fase II randomizado de radioterapia torácica 3D frente a la combinación de radioterapia torácica 3D y erlotinib (Tarceva®) en pacientes con carcinoma no microcítico de pulmón localiz...
    Medical condition: Carcinoma no microcítico de pulmón localizado irresecable o localmente avanzado, no susceptible de quimioterapia. Tratamiento combinado de radioterápica torácica y erlotinib y terapia de mantenimie...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018205-43 Sponsor Protocol Number: 0928 Start Date*: 2010-06-30
    Sponsor Name:Oncology Department
    Full Title: A clinical phase I / II trial of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer.
    Medical condition: Metastatic non small lungcancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:50:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA